Does Eric Devroe pay a price per share for the Acrivon (ACRV) RSU grant?

No, the reported RSU grant has a transaction price per share of $0.0000, indicating it is a compensation award rather than an open-market purchase. Each RSU represents a contingent right to receive one share of Common Stock upon vesting.

Acrivon (ACRV) COO Eric Devroe receives 72,981 RSU stock grant

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Devroe Eric reported acquisition or exercise transactions in this Form 4 filing.

Acrivon Therapeutics, Inc. reported that its Chief Operating Officer, Eric Devroe, received an equity award in the form of restricted stock units. On May 18, 2026, he was granted 72,981 shares of Common Stock at no cash cost as a compensation-related award.

These RSUs represent a contingent right to receive one share of Common Stock per unit. 16.67% of the RSUs will vest on November 18, 2026, with the remaining units vesting in 10 substantially equal quarterly installments, subject to his continued service. Following this award, Devroe directly holds 146,953 shares of Common Stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Devroe Eric

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	72,981	$0.00	--

Holdings After Transaction: Common Stock — 146,953 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

RSUs granted: 72,981 shares Holdings after transaction: 146,953 shares RSU vesting cliff: 16.67% +2 more

5 metrics

RSUs granted 72,981 shares Restricted stock unit award on May 18, 2026

Holdings after transaction 146,953 shares Common Stock directly held by Eric Devroe after grant

RSU vesting cliff 16.67% Portion vesting on November 18, 2026

Remaining vesting installments 10 quarterly installments Balance of RSUs vesting after November 18, 2026

Transaction price per share $0.0000/share Indicates compensation award, not open-market purchase

Key Terms

restricted stock units ("RSUs"), contingent right, vesting, substantially equal quarterly installments

4 terms

restricted stock units ("RSUs") financial

"These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right..."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

contingent right financial

"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."

vesting financial

"16.67% of the RSUs shall vest on November 18, 2026, and the remaining RSUs shall vest..."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

substantially equal quarterly installments financial

"the remaining RSUs shall vest in 10 substantially equal quarterly installments thereafter..."

Form 4 Insider Transactions: What Each Field Means →

05/20/2026 - 04:29 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Devroe Eric

(Last)

(First)

(Middle)

C/O ACRIVON THERAPEUTICS, INC.

480 ARSENAL WAY, SUITE 100

(Street)

WATERTOWN

MASSACHUSETTS

02472

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Acrivon Therapeutics, Inc. [ ACRV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/18/2026		A⁽¹⁾		72,981	A	$0	146,953	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Of these RSUs, 16.67% of the RSUs shall vest on November 18, 2026, and the remaining RSUs shall vest in 10 substantially equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date.

	/s/ Adam D. Levy, Attorney-in-Fact	05/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Acrivon Therapeutics (ACRV) report for Eric Devroe?

Acrivon reported that Chief Operating Officer Eric Devroe received a grant of 72,981 restricted stock units of Common Stock. The award is compensation-related, carries no cash exercise price, and increases his direct holdings to 146,953 shares after the transaction.

How many Acrivon (ACRV) shares did Eric Devroe hold after the Form 4 transaction?

After the reported grant, Eric Devroe directly held 146,953 shares of Acrivon Therapeutics Common Stock. This total includes the 72,981 restricted stock units awarded on May 18, 2026, which convert into shares as they vest over time.

What are the vesting terms of Eric Devroe’s Acrivon (ACRV) RSU award?

The RSU award vests over time. 16.67% of the restricted stock units vest on November 18, 2026, and the remaining units vest in 10 substantially equal quarterly installments, conditioned on Devroe’s continuous service through each vesting date.

What type of security was reported in Acrivon (ACRV) COO Eric Devroe’s Form 4?

The Form 4 reports restricted stock units linked to Acrivon’s Common Stock. Each RSU represents a contingent right to receive one share of Common Stock, subject to a vesting schedule beginning November 18, 2026, and continuing in quarterly installments.